Immunotherapies for glioblastoma
|Serial No.||Immune therapies||Observations||References|
|1||DCVax||Higher levels of tumor-associated antigens on GBM cells or a GBM stem cell population were linked to prolonged overall survival and progression-free survival|||
|2||PD-1 antibody||Treatment of malignancies melanoma, is used to block the immunological checkpoint. Immune checkpoint blockade, in contrast to employing CTL to fight cancer, shuts down the immune response in a way that allows depleted CTL to attack cancer|||
|3||MAbs (bevacizumab)||Block tumor blood vessels from growing and are also used for the treatment of a variety of cancers, including GBM|||
|4||NCAMs||Overexpression of NK-1R in glioma tumors has led to the development of NK-1R-targeted therapies for the treatment of glioma tumors|||
The authors acknowledge Jaypee Institute of Information Technology, Noida, for providing the entire infrastructure to complete this project.
M Singh and DJ contributed in conceptualization, design of the work, resourcing, interpretation of data. M Singh, DJ, VA, DP, M Sharma, and PP contributed to writing—original draft, and writing—review & editing; M Singh, SM, and R contributed in supervision; M Singh, DJ, SM and R contributed in data curation, and validation.
The authors declare that they have no conflicts of interest.
© The Author(s) 2022.